SINOVAC BIOTECH LTD (SVA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 7B 14B 21B FY09: 84.2M FY10: 33.4M FY11: 56.8M FY16: 72.4M FY17: 174.3M FY18: 229.7M FY19: 246.1M FY20: 510.6M FY21: 19.4B FY22: 1.5B FY23: 470.2M FY24: 361.4M FY25: 386M FY09 FY11 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 7B 14B 21B FY09: 64.1M FY10: 16.7M FY11: 35.7M FY12: 30.1M FY13: 51.3M FY14: 47.5M FY15: 49M FY16: 50M FY17: 154.1M FY18: 204.9M FY19: 213.6M FY20: 443.4M FY21: 18.4B FY22: 815.2M FY23: 323.3M FY24: 220.7M FY25: 262M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-6B 0 6B 12B 18B FY09: 42.1M FY10: -13.4M FY11: 3.4M FY12: -21.2M FY13: 9.9M FY14: 1.9M FY15: 3.7M FY16: 504K FY17: 45.4M FY18: 45.3M FY19: 68.6M FY20: 215.6M FY21: 17.6B FY22: -509M FY23: -714M FY24: -505.5M FY25: -490.1M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-3B 0 3B 6B 9B FY09: 20M FY10: -8.5M FY11: -844.7K FY12: -18.7M FY13: 7.4M FY14: -1.5M FY15: -1.4M FY16: -596K FY17: 25.8M FY18: 21.8M FY19: 44.9M FY20: 110.4M FY21: 8.1B FY22: 14.5M FY23: -13.5M FY24: 40.7M FY25: -198.8M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 350M 700M 1.1B FY09: 20.1M FY10: 16.7M FY11: 21.1M FY12: 19.1M FY13: 20.5M FY14: 15.5M FY15: 18.4M FY16: 22.4M FY17: 20.2M FY18: 24.7M FY19: 32.5M FY20: 67.2M FY21: 988.9M FY22: 658.2M FY23: 146.9M FY24: 140.7M FY25: 124M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-6B 0 6B 12B 18B FY09: 48.4M FY10: -14.3M FY11: 13.9M FY12: -16.3M FY13: 5.6M FY14: -10.1M FY15: 4.2M FY16: -13.9M FY17: 59.8M FY18: 7.9M FY19: 39.1M FY20: 479.3M FY21: 15.3B FY22: -798.1M FY23: 138.6M FY24: -56.9M FY25: -512.2M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-6B 0 6B 12B 18B FY09: 44.1M FY10: -39.1M FY11: -1.5M FY12: -32.4M FY13: 443K FY14: -21M FY15: -1.1M FY16: -26.6M FY17: 47.8M FY18: 2.3M FY19: 28.4M FY20: 351.8M FY21: 14.7B FY22: -1.1B FY23: -17.5M FY24: -152.9M FY25: -561.1M FY09 FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 40M 80M 120M FY09: 43M FY10: 53.1M FY11: 54.6M FY12: 54.9M FY13: 55.8M FY14: 56.1M FY15: 56.3M FY16: 56.9M FY17: 57.1M FY18: 65M FY19: 71.3M FY19: 109.7M FY20: 113.7M FY21: 71.6M FY22: 71.8M FY23: 71.9M FY24: 71.9M FY25: 71.9M FY10 FY12 FY14 FY16 FY18 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.